Morgan Stanley Innate Pharma Sa Call Options Transaction History
Morgan Stanley
- $1.39 Trillion
- Q4 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding IPHA
# of Institutions
10Shares Held
138KCall Options Held
0Put Options Held
0-
Exchange Traded Concepts, LLC77.4KShares$163,9820.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il11.9KShares$25,1280.0% of portfolio
-
Ubs Group Ag3.51KShares$7,4410.0% of portfolio
-
Rhumbline Advisers Boston, MA675Shares$1,4310.0% of portfolio
-
National Bank Of Canada450Shares$9540.0% of portfolio
About Innate Pharma SA
- Ticker IPHA
- Exchange OTC
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 79,893,000
- Market Cap $169M
- Description
- Innate Pharma S.A., a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and periphera...